CorMedix Announces the Initiation of Phase 3 Clinical Study for Neutrolin

CorMedix (NYSE MKT:CRMD) announces that it expects to begin the first Phase 3 study for Neutrolin in Q4 2015.
According to the press release:

The Phase 3 clinical trial is designed to be a U.S. multi-center, randomized, controlled study comparing Neutrolin to heparin in an estimated 633 patients in hemodialysis being monitored for catheter related bloodstream infections (CRBSI). Dr. Michael Allon, Professor, Department of Medicine, Division of Nephrology, University of Alabama, Birmingham will serve as the Study Chair.

Antony Pfaffle M.D., Chief Scientific Officer, commented:

Our discussions with the FDA and key opinion leaders have made clear that relatively high rates of infection continue to occur in hemodialysis, ICU/CCU and oncology patients who require central venous catheters. Our research and available data indicate that Neutrolin(R) may be able to address this problem, and we are pleased to advance this important clinical study.

Click here to read the full press release on CorMedix.